One‐Month Dual Antiplatelet Therapy After Bioresorbable Polymer Everolimus‐Eluting Stents in High Bleeding Risk Patients

One‐Month Dual Antiplatelet Therapy After Bioresorbable Polymer Everolimus‐Eluting Stents in High Bleeding Risk Patients

Background It is unknown whether contemporary drug‐eluting stents have a similar safety profile in high bleeding risk patients treated with 1‐month dual antiplatelet therapy following percutaneous coronary interventions. Methods and Results We performed an interventional, prospective, multicenter, s...

Full description

Bibliographic Details
Main Authors: Carlo A. Pivato, Bernhard Reimers, Luca Testa, Andrea Pacchioni, Carlo Briguori, Carmine Musto, Giovanni Esposito, Raffaele Piccolo, Luigi Lucisano, Leonardo De Luca, Federico Conrotto, Andrea De Marco, Anna Franzone, Patrizia Presbitero, Giuseppe Ferrante, Gerolama Condorelli, Valeria Paradies, Gennaro Sardella, Ciro Indolfi, Gianluigi Condorelli, Giulio G. Stefanini
Format: Article
Language:English
Published: Wiley 2022-03-01
Series:Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Subjects:
bioresorbable polymer stent
coronary artery disease
high bleeding risk
percutaneous coronary intervention
short DAPT
Synergy stent
Online Access:https://www.ahajournals.org/doi/10.1161/JAHA.121.023454

Internet

https://www.ahajournals.org/doi/10.1161/JAHA.121.023454

Similar Items